Loss of Notch1-dependent p21Waf1/Cip1 expression influences the Notch1 outcome in tumorigenesis

Cell Cycle

Volumn 13, Issue 13, 2014, Pages 2046-2245

  Cialfi, Samantha ^a   Palermo, Rocco ^b   Manca, Sonia ^a   De Blasio, Carlo ^a   Romero, Paula Vargas ^a   Checquolo, Saula ^c   Bellavia, Diana ^a   Uccelletti, Daniela ^c   Saliola, Michele ^c   D'Alessandro, Angelo ^d   Zolla, Lello ^d   Gulino, Alberto ^a,b,e   Screpanti, Isabella ^a   Talora, Claudio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF TUSCIA   (Italy)

^e IRCCS NEUROMED   (Italy)

Author keywords

Metabolism; Notch; Nrf2; p21

Indexed keywords

ARSENIC; ARSENIC TRIOXIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1; NOTCH1 RECEPTOR; REACTIVE OXYGEN METABOLITE; VASCULAR TARGETING AGENT; ARSENOUS ACID DERIVATIVE; CDKN1A PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; F BOX PROTEIN; FBXW7 PROTEIN, HUMAN; MICRORNA; MIRN223 MICRORNA, HUMAN; MYC PROTEIN; MYC PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; NOTCH1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR NRF2; UBIQUITIN PROTEIN LIGASE;

ARTICLE; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; CYTOLOGY; DOWN REGULATION; DRUG EXPOSURE; HOMEOSTASIS; HUMAN; HUMAN CELL; KERATINOCYTE; LONG TERM EXPOSURE; ONCOGENE C MYC; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; SKIN CARCINOGENESIS; UPREGULATION; APOPTOSIS; CELL LINE; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; TOXICITY;

APOPTOSIS; ARSENITES; CARCINOGENESIS; CELL CYCLE PROTEINS; CELL LINE; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; F-BOX PROTEINS; HUMANS; KERATINOCYTES; MICRORNAS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-MYC; REACTIVE OXYGEN SPECIES; RECEPTOR, NOTCH1; UBIQUITIN-PROTEIN LIGASES;

EID: 84903756189     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.29079     Document Type: Article

References (57)

1. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011; 333:1154-7; PMID:21798897; http://dx.doi.org/10.1126/science.1206923
2. Talora C, Campese AF, Bellavia D, Felli MP, Vacca A, Gulino A, Screpanti I. Notch signaling and diseases: an evolutionary journey from a simple beginning to complex outcomes. Biochim Biophys Acta 2008; 1782:489-97; PMID:18625307; http://dx.doi.org/10.1016/j.bbadis.2008.06.008
3. Mazzone M, Selfors LM, Albeck J, Overholtzer M, Sale S, Carroll DL, Pandya D, Lu Y, Mills GB, Aster JC, et al. Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc Natl Acad Sci U S A 2010; 107:5012-7; PMID:20194747; http://dx.doi.org/10. 1073/pnas.1000896107
4. Talora C, Cialfi S, Segatto O, Morrone S, Kim Choi J, Frati L, Paolo Dotto G, Gulino A, Screpanti I. Constitutively active Notch1 induces growth arrest of HPV-positive cervical cancer cells via separate signaling pathways. Exp Cell Res 2005; 305:343-54; PMID:15817159; http://dx.doi.org/10.1016/j.yexcr. 2005.01.015
5. Biolcati G, Aurizi C, Barbieri L, Cialfi S, Screpanti I, Talora C. Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clin Exp Dermatol 2014; 39:168-75; PMID:24256215; http://dx.doi.org/10.1111/ced.12203
6. Cialfi S, Oliviero C, Ceccarelli S, Marchese C, Barbieri L, Biolcati G, Uccelletti D, Palleschi C, Barboni L, De Bernardo C, et al. Complex multipathways alterations and oxidative stress are associated with Hailey-Hailey disease. Br J Dermatol 2010; 162:518-26; PMID:19903178; http://dx.doi.org/10. 1111/j.1365-2133.2009.09500.x
7. Manca S, Magrelli A, Cialfi S, Lefort K, Ambra R, Alimandi M, Biolcati G, Uccelletti D, Palleschi C, Screpanti I, et al. Oxidative stress activation of miR-125b is part of the molecular switch for Hailey-Hailey disease manifestation. Exp Dermatol 2011; 20:932-7; PMID:21913998; http://dx.doi.org/10. 1111/j.1600-0625.2011.01359.x
8. Jaramillo MC, Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev 2013; 27:2179-91; PMID:24142871; http://dx.doi.org/10.1101/gad.225680.113
9. Naviaux RK. Oxidative shielding or oxidative stress? J Pharmacol Exp Ther 2012; 342:608-18; PMID:22700427; http://dx.doi.org/10.1124/jpet.112.192120
10. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 2013; 12:931-47; PMID:24287781; http://dx.doi.org/10.1038/nrd4002
11. Giambra V, Jenkins CR, Wang H, Lam SH, Shevchuk OO, Nemirovsky O, Wai C, Gusscott S, Chiang MY, Aster JC, et al. NOTCH1 promotes T cell leukemiainitiating activity by RUNX-mediated regulation of PKC-θ and reactive oxygen species. Nat Med 2012; 18:1693-8; PMID:23086478; http://dx.doi.org/10.1038/nm.2960
12. Pi J, Diwan BA, Sun Y, Liu J, Qu W, He Y, Styblo M, Waalkes MP. Arsenic-induced malignant transformation of human keratinocytes: involvement of Nrf2. Free Radic Biol Med 2008; 45:651-8; PMID:18572023; http://dx.doi.org/10. 1016/j.freeradbiomed.2008.05.020
13. Wakabayashi N, Shin S, Slocum SL, Agoston ES, Wakabayashi J, Kwak MK, Misra V, Biswal S, Yamamoto M, Kensler TW. Regulation of notch1 signaling by nrf2: implications for tissue regeneration. Sci Signal 2010; 3:ra52; PMID:20628156; http://dx.doi.org/10.1126/scisignal.2000762
14. Liu H, Talalay P. Relevance of anti-inflammatory and antioxidant activities of exemestane and synergism with sulforaphane for disease prevention. Proc Natl Acad Sci U S A 2013; 110:19065-70; PMID:24191056; http://dx.doi.org/10.1073/pnas.1318247110
15. Wu KC, McDonald PR, Liu J, Klaassen CD. Screening of natural compounds as activators of the keap1-nrf2 pathway. Planta Med 2014; 80:97-104; PMID:24310212
16. Dangleben NL, Skibola CF, Smith MT. Arsenic immunotoxicity: a review. Environ Health 2013; 12:73; PMID:24004508; http://dx.doi.org/10.1186/1476-069X- 12-73
17. Mansour MR, Sulis ML, Duke V, Foroni L, Jenkinson S, Koo K, Allen CG, Gale RE, Buck G, Richards S, et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol 2009; 27:4352-6; PMID:19635999; http://dx.doi.org/10.1200/JCO.2009.22.0996
18. O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, Hardwick J, Welcker M, Meijerink JP, Pieters R, et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 2007; 204:1813-24; PMID:17646409; http://dx.doi.org/10.1084/jem. 20070876
19. Tsunematsu R, Nakayama K, Oike Y, Nishiyama M, Ishida N, Hatakeyama S, Bessho Y, Kageyama R, Suda T, Nakayama KI. Mouse Fbw7/Sel-10/Cdc4 is required for notch degradation during vascular development. J Biol Chem 2004; 279:9417-23; PMID:14672936; http://dx.doi.org/10.1074/jbc.M312337200
20. Mansour MR, Sanda T, Lawton LN, Li X, Kreslavsky T, Novina CD, Brand M, Gutierrez A, Kelliher MA, Jamieson CH, et al. The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia. J Exp Med 2013; 210:1545-57; PMID:23857984; http://dx.doi.org/10.1084/ jem.20122516
21. Dotto GP. p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta 2000; 1471:M43-56; PMID:10967424
22. Warfel NA, El-Deiry WS. p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol 2013; 25:52-8; PMID:23159848; http://dx.doi.org/10.1097/CCO. 0b013e32835b639e
23. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002; 1:639-49; PMID:12479224
24. Rangarajan A, Talora C, Okuyama R, Nicolas M, Mammucari C, Oh H, Aster JC, Krishna S, Metzger D, Chambon P, et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J 2001; 20:3427-36; PMID:11432830; http://dx.doi.org/10.1093/emboj/20.13.3427
25. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci U S A 1995; 92:5545-9; PMID:7777546; http://dx.doi.org/10.1073/pnas.92.12.5545
26. Yan W, Zhang Y, Zhang J, Liu S, Cho SJ, Chen X. Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression. J Biol Chem 2011; 286:17478-86; PMID:21454520; http://dx.doi.org/ 10.1074/jbc.M111.231639
27. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9:400-14; PMID:19440234; http://dx.doi.org/10. 1038/nrc2657
28. Masgras I, Carrera S, de Verdier PJ, Brennan P, Majid A, Makhtar W, Tulchinsky E, Jones GD, Roninson IB, Macip S. Reactive oxygen species and mitochondrial sensitivity to oxidative stress determine induction of cancer cell death by p21. J Biol Chem 2012; 287:9845-54; PMID:22311974; http://dx.doi.org/10.1074/jbc.M111.250357
29. Villeneuve NF, Sun Z, Chen W, Zhang DD. Nrf2 and p21 regulate the fine balance between life and death by controlling ROS levels. Cell Cycle 2009; 8:3255-6; PMID:19806015; http://dx.doi.org/10.4161/cc.8.20.9565
30. Dang CV. Links between metabolism and cancer. Genes Dev 2012; 26:877-90; PMID:22549953; http://dx.doi.org/10.1101/gad.189365.112
31. Riganti C, Gazzano E, Polimeni M, Aldieri E, Ghigo D. The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate. Free Radic Biol Med 2012; 53:421-36; PMID:22580150; http://dx.doi.org/10.1016/j. freeradbiomed.2012.05.006
32. Dang CV. MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med 2013; 3.
33. Le A, Dang CV. Studying Myc's role in metabolism regulation. Methods Mol Biol 2013; 1012:213-9; PMID:24006067; http://dx.doi.org/10.1007/978-1-62703-429- 6-14
34. Mitsuishi Y, Motohashi H, Yamamoto M. The Keap1-Nrf2 system in cancers: stress response and anabolic metabolism. Front Oncol 2012; 2:200; PMID:23272301; http://dx.doi.org/10.3389/fonc.2012.00200
35. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, Yamamoto M, Motohashi H. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 2012; 22:66-79; PMID:22789539; http://dx.doi.org/10.1016/j.ccr.2012.05.016
36. Klinakis A, Szabolcs M, Politi K, Kiaris H, Artavanis-Tsakonas S, Efstratiadis A. Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proc Natl Acad Sci U S A 2006; 103:9262-7; PMID:16751266; http://dx.doi.org/10.1073/pnas.0603371103
37. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, Barnes KC, O'Neil J, Neuberg D, Weng AP, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A 2006; 103:18261-6; PMID:17114293; http://dx.doi.org/10.1073/pnas.0606108103
38. Rakowski LA, Garagiola DD, Li CM, Decker M, Caruso S, Jones M, Kuick R, Cierpicki T, Maillard I, Chiang MY. Convergence of the ZMIZ1 and NOTCH1 pathways at C-MYC in acute T lymphoblastic leukemias. Cancer Res 2013; 73:930-41; PMID:23161489; http://dx.doi.org/10.1158/0008-5472.CAN-12-1389
39. Louvi A, Artavanis-Tsakonas S. Notch and disease: a growing field. Semin Cell Dev Biol 2012; 23:473-80; PMID:22373641; http://dx.doi.org/10.1016/j. semcdb.2012.02.005
40. South AP, Cho RJ, Aster JC. The double-edged sword of Notch signaling in cancer. Semin Cell Dev Biol 2012; 23:458-64; PMID:22309843; http://dx.doi.org/ 10.1016/j.semcdb.2012.01.017
41. Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, Hui CC, Clevers H, Dotto GP, Radtke F. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 2003; 33:416-21; PMID:12590261; http://dx.doi.org/10.1038/ng1099
42. Pear WS, Aster JC, Scott ML, Hasserjian RP, Soffer B, Sklar J, Baltimore D. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med 1996; 183:2283-91; PMID:8642337; http://dx.doi.org/10.1084/jem.183.5.2283
43. Jhappan C, Gallahan D, Stahle C, Chu E, Smith GH, Merlino G, Callahan R. Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands. Genes Dev 1992; 6:345-55; PMID:1372276; http://dx.doi.org/10.1101/gad.6. 3.345
44. Uyttendaele H, Marazzi G, Wu G, Yan Q, Sassoon D, Kitajewski J. Notch4/int-3, a mammary protooncogene, is an endothelial cell-specific mammalian Notch gene. Development 1996; 122:2251-9; PMID:8681805
45. Lefort K, Mandinova A, Ostano P, Kolev V, Calpini V, Kolfschoten I, Devgan V, Lieb J, Raffoul W, Hohl D, et al. Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. Genes Dev 2007; 21:562-77; PMID:17344417; http://dx.doi.org/10.1101/gad.1484707
46. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489:519-25; PMID:22960745; http://dx.doi.org/10.1038/nature11404
47. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011; 333:1157-60; PMID:21798893; http://dx.doi.org/10.1126/science.1208130
48. Wang NJ, Sanborn Z, Arnett KL, Bayston LJ, Liao W, Proby CM, Leigh IM, Collisson EA, Gordon PB, Jakkula L, et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc Natl Acad Sci U S A 2011; 108:17761-6; PMID:22006338; http://dx.doi.org/10.1073/pnas.1114669108
49. Sun W, Gaykalova DA, Ochs MF, Mambo E, Arnaoutakis D, Liu Y, Loyo M, Agrawal N, Howard J, Li R, et al. Activation of the NOTCH pathway in head and neck cancer. Cancer Res 2014; 74:1091-104; PMID:24351288; http://dx.doi.org/10. 1158/0008-5472.CAN-13-1259
50. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, Chen H. Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J Biol Chem 2006; 281:39819-30; PMID:17090547; http://dx.doi.org/10.1074/jbc.M603578200
51. Mammucari C, Tommasi di Vignano A, Sharov AA, Neilson J, Havrda MC, Roop DR, Botchkarev VA, Crabtree GR, Dotto GP. Integration of Notch 1 and calcineurin/NFAT signaling pathways in keratinocyte growth and differentiation control. Dev Cell 2005; 8:665-76; PMID:15866158; http://dx.doi.org/10.1016/j. devcel.2005.02.016
52. Sriuranpong V, Borges MW, Ravi RK, Arnold DR, Nelkin BD, Baylin SB, Ball DW. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res 2001; 61:3200-5; PMID:11306509
53. Gartel AL, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F, Tyner AL. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci U S A 2001; 98:4510-5; PMID:11274368; http://dx.doi.org/10.1073/pnas. 081074898
54. Oskarsson T, Essers MA, Dubois N, Offner S, Dubey C, Roger C, Metzger D, Chambon P, Hummler E, Beard P, et al. Skin epidermis lacking the c-Myc gene is resistant to Ras-driven tumorigenesis but can reacquire sensitivity upon additional loss of the p21Cip1 gene. Genes Dev 2006; 20:2024-9; PMID:16882980; http://dx.doi.org/10.1101/gad.381206
55. Haraguchi K, Suzuki T, Koyama N, Kumano K, Nakahara F, Matsumoto A, Yokoyama Y, Sakata-Yanagimoto M, Masuda S, Takahashi T, et al. Notch activation induces the generation of functional NK cells from human cord blood CD34-positive cells devoid of IL-15. J Immunol 2009; 182:6168-78; PMID:19414770; http://dx.doi.org/10.4049/jimmunol.0803036
56. Kumar V, Palermo R, Talora C, Campese AF, Checquolo S, Bellavia D, Tottone L, Testa G, Miele E, Indraccolo S, et al. Notch and NF-kB signaling pathways regulate miR-223/FBXW7 axis in T cell acute lymphoblastic leukemia. Leukemia 2014; PMID:24727676; http://dx.doi.org/10.1038/leu.2014.133
57. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 1988; 106:761-71; PMID:2450098; http://dx.doi.org/10.1083/jcb.106.3.761